5.17 USD
▲+0.04+2.17%
盘后 5.12 +1.33%
2026-08-03
市值
$141.62M
市盈率
—
EPS
-2.11
股息率
—
52 周区间
3.71 – 8.74
成交量
858.38K
Beta
1.79
目标价
38.59
52W 低 3.7152W 高 8.74
价格走势
公司简介
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj...